Charmacy Pharmaceutical Management
Management criteria checks 4/4
Charmacy Pharmaceutical's CEO is Chuanglong Yao, appointed in Mar 2000, has a tenure of 24.75 years. total yearly compensation is CN¥728.07K, comprised of 87.4% salary and 12.6% bonuses, including company stock and options. directly owns 31.97% of the company’s shares, worth HK$310.77M. The average tenure of the management team and the board of directors is 2.7 years and 5.8 years respectively.
Key information
Chuanglong Yao
Chief executive officer
CN¥728.1k
Total compensation
| CEO salary percentage | 87.4% |
| CEO tenure | 24.8yrs |
| CEO ownership | 32.0% |
| Management average tenure | 2.7yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥52m |
| Mar 31 2024 | n/a | n/a | CN¥52m |
| Dec 31 2023 | CN¥728k | CN¥636k | CN¥51m |
| Sep 30 2023 | n/a | n/a | CN¥74m |
| Jun 30 2023 | n/a | n/a | CN¥96m |
| Mar 31 2023 | n/a | n/a | CN¥93m |
| Dec 31 2022 | CN¥732k | CN¥638k | CN¥90m |
| Sep 30 2022 | n/a | n/a | CN¥54m |
| Jun 30 2022 | n/a | n/a | CN¥18m |
| Mar 31 2022 | n/a | n/a | CN¥20m |
| Dec 31 2021 | CN¥679k | CN¥646k | CN¥23m |
| Sep 30 2021 | n/a | n/a | CN¥29m |
| Jun 30 2021 | n/a | n/a | CN¥36m |
| Mar 31 2021 | n/a | n/a | CN¥38m |
| Dec 31 2020 | CN¥685k | CN¥649k | CN¥41m |
| Sep 30 2020 | n/a | n/a | CN¥35m |
| Jun 30 2020 | n/a | n/a | CN¥29m |
| Mar 31 2020 | n/a | n/a | CN¥34m |
| Dec 31 2019 | CN¥714k | CN¥650k | CN¥40m |
| Sep 30 2019 | n/a | n/a | CN¥41m |
| Jun 30 2019 | n/a | n/a | CN¥42m |
| Mar 31 2019 | n/a | n/a | CN¥44m |
| Dec 31 2018 | CN¥715k | CN¥649k | CN¥45m |
Compensation vs Market: Chuanglong's total compensation ($USD99.76K) is below average for companies of similar size in the Hong Kong market ($USD231.54K).
Compensation vs Earnings: Chuanglong's compensation has been consistent with company performance over the past year.
CEO
Chuanglong Yao (54 yo)
24.8yrs
Tenure
CN¥728,071
Compensation
Mr. Chuanglong Yao has been Chief Executive Officer at Charmacy Pharmaceutical Co., Ltd. since March 2000 and serves as its Vice Chairman since May 31, 2023 and served as its Chairman since May 2015. Mr. Y...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Vice Chairman | 24.8yrs | CN¥728.07k | 31.97% HK$ 310.8m | |
| CFO & Executive Director | 2.7yrs | CN¥385.49k | no data | |
| VP & Executive Director | 9.3yrs | CN¥991.13k | no data | |
| Chief Logistics Officer & CTO | no data | CN¥188.00k | no data | |
| Joint Company Secretary | 2.7yrs | no data | no data | |
| Joint Company Secretary | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
45yo
Average Age
Experienced Management: 2289's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Vice Chairman | 24.8yrs | CN¥728.07k | 31.97% HK$ 310.8m | |
| CFO & Executive Director | 2.4yrs | CN¥385.49k | no data | |
| VP & Executive Director | 9.6yrs | CN¥991.13k | no data | |
| Independent Non-Executive Director | 9yrs | CN¥144.00k | no data | |
| Independent Non-Executive Director | 9yrs | CN¥50.00k | no data | |
| Independent Supervisor | 9.6yrs | no data | no data | |
| Employee Representative Supervisor | 9.6yrs | no data | no data | |
| Independent Non-Executive Director | 1.6yrs | CN¥29.30k | no data | |
| Non-Executive Director | 2.4yrs | no data | no data | |
| Non-Executive Chairman | 2.5yrs | no data | no data | |
| Non-Executive Director | 1.6yrs | no data | no data | |
| Chairman of the Board of Supervisors | 1.6yrs | no data | no data |
5.8yrs
Average Tenure
49yo
Average Age
Experienced Board: 2289's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 19:32 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Charmacy Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|